KIN News and Press, Kindred Biosciences Inc. From 12/20/20

Ariel Investments’ 13F portfolio value increased from $6.57B to $6.89B this quarter. They increased Gilead Sciences while reducing ViacomCBS during the quarter. The top three positions are Baidu, Philip Morris, and Microsoft and they add up to ~15% of the portfolio. F...

Elanco Animal Health (ELAN) has entered into an agreement with Kindred Biosciences (KIN) to acquire exclusive global rights to KIND-030, a monoclonal antibody being developed for canine parvovirus.Global license includes an upfront payment of $500k, development milestone payments of up t...

Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody SAN FRANCISCO , Dec. 11, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving ...

Kindred Biosciences to Present at Guggenheim Animal Health Summit SAN FRANCISCO , Dec. 2, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Ric...

Kindred Biosciences (KIN) -3.2% after-hours as it discloses the suspension of its feline recombinant erythropoietin program following an "adverse event."Citing the impact of safety profile on the program's potential commercial value as well as the rapid growth of the canine dermatitis market,...

Kindred Biosciences to Participate in Stifel Virtual Healthcare Conference and A.G.P. Virtual Healthcare Symposium PR Newswire SAN FRANCISCO, Nov. 11, 2020 SAN FRANCISCO , Nov. 11, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharma...

Kindred Biosciences, Inc. (KIN) Q3 2020 Earnings Conference Call November 09, 2020, 16:30 PM ET Company Participants Richard Chin - Co-Founder and Chief Executive Officer Wendy Wee - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners David Westenberg - ...

Kindred Biosciences (KIN): Q3 GAAP EPS of -$0.31 misses by $0.01.Revenue of $1M (-9.1% Y/Y) beats by $0.44M.Press Release For further details see: Kindred Biosciences EPS misses by $0.01, beats on revenue

Kindred Biosciences Announces Third Quarter 2020 Financial Results PR Newswire SAN FRANCISCO, Nov. 9, 2020 SAN FRANCISCO , Nov. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the li...

Kindred Biosciences to Announce Third Quarter 2020 Financial Results Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, November 9, 2020. PR Newswire SAN FRANCISCO, Oct. 28, 2020 SAN FRANCISCO , Oct. 28, ...